Welcome to our dedicated page for Quince news (Ticker: QNCX), a resource for investors and traders seeking the latest updates and insights on Quince stock.
Quince Therapeutics reports biotechnology, clinical-development and corporate restructuring updates tied to its rare-disease focus. The company’s AIDE technology is a drug/device platform designed to encapsulate drugs in a patient’s own red blood cells, and its lead asset eDSP has been studied in Ataxia-Telangiectasia, a rare pediatric neurodegenerative disease.
Recurring news includes eDSP clinical data, scientific presentations and publications, business updates, financial results, debt-settlement activity and the company’s evaluation of strategic alternatives. Recent company communications also reflect the decision to cease clinical development of eDSP following Phase 3 NEAT trial results and to preserve cash while reviewing available corporate options.
Quince Therapeutics (Nasdaq: QNCX) announced settlement of its European Investment Bank loan obligations effective March 27, 2026. The company paid $5.5 million to fully satisfy approximately $16.4 million of outstanding EIB debt, enabling restructuring and evaluation of strategic alternatives.
Management says the settlement removes a substantial overhang that constrained flexibility and supports pursuit of merger, reverse merger, asset sale, or other strategic transactions aimed at maximizing shareholder value.
Quince Therapeutics (Nasdaq: QNCX) engaged LifeSci Capital as its exclusive financial advisor on February 9, 2026 to evaluate strategic alternatives and assist with restructuring of the company’s liabilities.
Options under review may include partnerships, joint ventures, mergers, acquisitions, licensing, or other strategic transactions; the company will not comment further until the Board approves any specific action.
Quince Therapeutics (Nasdaq: QNCX) reported topline results from the pivotal Phase 3 NEAT trial of eDSP in Ataxia-Telangiectasia. The trial (n=105) failed to meet the primary RmICARS endpoint (difference -1.30; p=0.0851) and a key secondary CGI-S endpoint (p=0.522).
eDSP was generally well tolerated with no clinically meaningful safety concerns. The company will cease clinical development of eDSP and intends to preserve cash while exploring available options.
Quince Therapeutics (NASDAQ: QNCX) presented previously published safety data on long-term eDSP in children with Ataxia-Telangiectasia at the British Paediatric Neurology Association Annual Meeting, Glasgow, January 28-30, 2026.
Key highlights: stable height and weight z-scores, no corticosteroid-related growth suppression or weight gain, no adrenal insufficiency confirmed, and no glucose homeostasis concerns; routine monitoring recommended.
Quince Therapeutics (Nasdaq: QNCX) announced the last patient last visit in its pivotal Phase 3 NEAT trial of encapsulated dexamethasone sodium phosphate (eDSP) for Ataxia-Telangiectasia (A-T).
The company enrolled 105 participants (83 in the 6–9 year primary cohort; 22 aged ≥10), executed the study under a Special Protocol Assessment, and reports low discontinuation rates and an independent data safety monitoring board that met three times with no safety concerns. Quince expects to report topline results in the middle of Q1 2026. Most participants (all but one) transitioned to an open-label extension.
Quince Therapeutics (Nasdaq: QNCX) announced publication in Frontiers in Drug Delivery summarizing eight early-stage clinical trials of its lead asset eDSP (dexamethasone sodium phosphate encapsulated in autologous red blood cells) in pulmonary and inflammatory bowel disorders.
Key findings: eDSP was dosed every two weeks or monthly across ages 5–83, produced improved FEV1 and fewer infections in cystic fibrosis, improved COPD symptoms with lower steroid exposure, enabled corticosteroid withdrawal in 60%–78% of IBD patients, and showed DSP levels persisting up to 28 days post-infusion; mean infusion dose did not exceed 10 mg.
Quince Therapeutics (Nasdaq: QNCX) announced senior management will participate in three investor events in December 2025: a Piper Sandler fireside chat on Dec 3, 2025 at 10:30 AM ET, a panel at the Oppenheimer Movers in Rare Disease Summit on Dec 11, 2025, and a virtual Lunch with LifeSci fireside chat on Dec 16, 2025 at 1:00 PM ET. Presenters include Dirk Thye, M.D. (CEO & CMO), Charles Ryan, J.D., Ph.D. (President), and Brendan Hannah (COO & CBO). The Piper Sandler and LifeSci sessions will be webcast with archives available, and the Oppenheimer panel highlights near-term catalysts as Quince advances toward pivotal Phase 3 NEAT topline results expected in Q1 2026.
Quince Therapeutics (Nasdaq: QNCX) reported Q3 2025 results and a business update. The company completed enrollment in its pivotal Phase 3 NEAT trial with 105 total participants (83 in the six-to-nine year-old primary analysis group) and expects topline results in Q1 2026. The trial operates under an FDA SPA, has FDA Fast Track designation, and an iDSMB recommended continuation without modification; 100% of participants elected the open-label extension.
Q3 cash, cash equivalents, and short-term investments totaled $26.3M, with a cash runway expected into Q2 2026 (potential extension into H2 2026 if warrants are exercised). Q3 net loss was $13.3M (loss per share $0.25).
Quince Therapeutics (Nasdaq: QNCX) reported a positive pre-planned safety review by an independent data and safety monitoring board (iDSMB) for its pivotal Phase 3 NEAT trial of encapsulated dexamethasone sodium phosphate (eDSP) in patients with Ataxia-Telangiectasia (A-T).
The iDSMB found no safety concerns and recommended the study continue without modifications. The international, multicenter, randomized, double-blind, placebo-controlled trial enrolls two cohorts (1:1 randomization) with six infusions given every 21–30 days. The primary endpoint is change from baseline to last efficacy visit on the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS). Quince expects to report topline results in Q1 2026.
Quince Therapeutics (Nasdaq: QNCX) presented a poster on patient‑reported walking capacity in children with Ataxia‑Telangiectasia (A‑T) at the 54th Child Neurology Society Annual Meeting on October 9, 2025.
The cross‑sectional natural history analysis used data from 372 children in the Global A‑T Family Data Platform to describe age‑related loss of ambulation. A patient‑reported walking scale was compared with clinician measures ICARS and RmICARS, showing all three scales tracked walking decline similarly. Findings suggest the RmICARS walking components may be suitable for assessing A‑T disease progression and are relevant to the company's Phase 3 NEAT trial of encapsulated dexamethasone sodium phosphate (eDSP, NCT06193200).